Syngene, a global contract research, development, and manufacturing organization (CRDMO), recently announced the acquisition of its first biologics site in the USA –...

Germany-headquartered Rentschler Biopharma, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of...

Anglo-Swedish drugmaker AstraZeneca plans to invest $3.5 billion in the US to expand the company’s research and manufacturing footprint by the end of 2026.

OneSource Specialty Pharma, a newly incorporated CDMO, formed from the merger of three CDMO businesses within the Strides Group. The company has a 30-year track record...

Eli Lilly and Company (Lilly) recently announced a $4.5 billion (€4.07 billion) investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing...

Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and...

Bill Humphries, CEO of Alcami, shares his vision for the future, discussing dynamic market trends and the company’s commitment to innovation. Under his leadership, Alcami...

Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product...